{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:39:57Z","timestamp":1788309597144,"version":"build-2803163510"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The spectrum of acquired pediatric demyelinating syndromes has been expanding over the past few years, to include myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as a distinct neuroimmune entity, in addition to pediatric-onset multiple sclerosis (POMS) and aquaporin 4-IgG-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD). The 2023 MOGAD diagnostic criteria require supporting clinical or magnetic resonance imaging (MRI) features in patients with low positive myelin oligodendrocyte glycoprotein IgG titers or when the titers are not available, highlighting the diagnostic role of imaging in MOGAD. In this review, we summarize the key diagnostic features in MOGAD, in comparison to POMS and AQP4+NMOSD. We describe the lesion dynamics both during attack and over time. Finally, we propose a guideline on timing of imaging in clinical practice.<\/jats:p>","DOI":"10.1007\/s00247-024-06023-2","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T11:01:56Z","timestamp":1725706916000},"page":"699-720","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease\u2014diagnostic criteria and lesion dynamics"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4576-086X","authenticated-orcid":false,"given":"Li-tal","family":"Pratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-5679","authenticated-orcid":false,"given":"Hadas","family":"Meirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-7673","authenticated-orcid":false,"given":"Mika","family":"Shapira Rootman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-0190","authenticated-orcid":false,"given":"Liat","family":"Ben-Sira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-5107","authenticated-orcid":false,"given":"Shelly I","family":"Shiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"issue":"2","key":"6023_CR1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000081","volume":"2","author":"Y Hacohen","year":"2015","unstructured":"Hacohen Y, Absoud M, Deiva K et al (2015) Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2(2):e81. https:\/\/doi.org\/10.1212\/NXI.0000000000000081. (Published 2015 Mar 12)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"6023_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15(4):307\u2013324. https:\/\/doi.org\/10.1016\/j.autrev.2015.12.004","journal-title":"Autoimmun Rev"},{"issue":"8","key":"6023_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.118","volume":"9","author":"M Reindl","year":"2013","unstructured":"Reindl M, Di Pauli F, Rost\u00e1sy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9(8):455461. https:\/\/doi.org\/10.1038\/nrneurol.2013.118","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"6023_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473\u2013477. https:\/\/doi.org\/10.1084\/jem.20050304","journal-title":"J Exp Med"},{"issue":"2","key":"6023_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nm1488","volume":"13","author":"KC O'Connor","year":"2007","unstructured":"O\u2019Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13(2):211\u2013217. https:\/\/doi.org\/10.1038\/nm1488","journal-title":"Nat Med"},{"key":"6023_CR6","doi-asserted-by":"publisher","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease [published correction appears in Lancet Neurol. 2021 Oct;20(10).  https:\/\/doi.org\/10.1016\/S1474-4422(21)00290-8] [published correction appears in Lancet Neurol. 2022 Jan;21(1).  https:\/\/doi.org\/10.1016\/S1474-4422(21)00433-6]. Lancet Neurol 20(9):762\u2013772. https:\/\/doi.org\/10.1016\/S1474-4422(21)00218-0","DOI":"10.1016\/S1474-4422(21)00218-0"},{"issue":"5","key":"6023_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102801","volume":"20","author":"FV Pereira","year":"2021","unstructured":"Pereira FV, Jarry VM, Castro JTS, Appenzeller S, Reis F (2021) Pediatric inflammatory demyelinating disorders and mimickers: how to differentiate with MRI? Autoimmun Rev 20(5):102801. https:\/\/doi.org\/10.1016\/j.autrev.2021.102801","journal-title":"Autoimmun Rev"},{"issue":"3","key":"6023_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria. Lancet Neurol 22(3):268\u2013282. https:\/\/doi.org\/10.1016\/S1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"issue":"13","key":"6023_CR9","doi-asserted-by":"publisher","first-page":"e1376","DOI":"10.1212\/WNL.0000000000207478","volume":"101","author":"L Cacciaguerra","year":"2023","unstructured":"Cacciaguerra L, Redenbaugh V, Chen JJ et al (2023) Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease. Neurology 101(13):e1376\u2013e1381. https:\/\/doi.org\/10.1212\/WNL.0000000000207478","journal-title":"Neurology"},{"issue":"10","key":"6023_CR10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209303","volume":"102","author":"L Cacciaguerra","year":"2024","unstructured":"Cacciaguerra L, Abdel-Mannan O, Champsas D et al (2024) Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease. Neurology 102(10):e209303. https:\/\/doi.org\/10.1212\/WNL.0000000000209303","journal-title":"Neurology"},{"issue":"5","key":"6023_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1136\/jnnp-2023-332542","volume":"95","author":"O Abdel-Mannan","year":"2024","unstructured":"Abdel-Mannan O, Champsas D, Tur C et al (2024) Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course. J Neurol Neurosurg Psychiatry 95(5):426\u2013433. https:\/\/doi.org\/10.1136\/jnnp-2023-332542. (Published 2024 Apr 12)","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"6023_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1352458519845112","volume":"26","author":"CL de Mol","year":"2020","unstructured":"de Mol CL, Wong Y, van Pelt ED et al (2020) The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. Mult Scler 26(7):806\u2013814. https:\/\/doi.org\/10.1177\/1352458519845112","journal-title":"Mult Scler"},{"issue":"9","key":"6023_CR13","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","volume":"89","author":"EM Hennes","year":"2017","unstructured":"Hennes EM, Baumann M, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89(9):900\u2013908. https:\/\/doi.org\/10.1212\/WNL.0000000000004312","journal-title":"Neurology"},{"issue":"4","key":"6023_CR14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00415-018-8781-3","volume":"265","author":"M Baumann","year":"2018","unstructured":"Baumann M, Grams A, Djurdjevic T et al (2018) MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol 265(4):845\u2013855. https:\/\/doi.org\/10.1007\/s00415-018-8781-3","journal-title":"J Neurol"},{"key":"6023_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.885218","volume":"13","author":"E Sechi","year":"2022","unstructured":"Sechi E, Cacciaguerra L, Chen JJ et al (2022) Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol 13:885218. https:\/\/doi.org\/10.3389\/fneur.2022.885218. (Published 2022 Jun 17)","journal-title":"Front Neurol"},{"key":"6023_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.752557","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Xie H, Zhang J et al (2021) Clinical and radiological characteristics of children and adults with first-attack myelin oligodendrocyte glycoprotein antibody disease and analysis of risk factors for predicting the severity at disease onset in Central China. Front Immunol 12:752557. https:\/\/doi.org\/10.3389\/fimmu.2021.752557. (Published 2021 Dec 15)","journal-title":"Front Immunol"},{"key":"6023_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2023.101057","volume":"46","author":"JN Brenton","year":"2023","unstructured":"Brenton JN (2023) The evolving spectrum of inflammatory demyelination of the central nervous system in children. Semin Pediatr Neurol 46:101057. https:\/\/doi.org\/10.1016\/j.spen.2023.101057","journal-title":"Semin Pediatr Neurol"},{"key":"6023_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2023.101056","volume":"46","author":"MM Khoshnood","year":"2023","unstructured":"Khoshnood MM, Santoro JD (2023) Myelin oligodendrocyte glycoprotein (MOG) associated diseases: updates in pediatric practice. Semin Pediatr Neurol 46:101056. https:\/\/doi.org\/10.1016\/j.spen.2023.101056","journal-title":"Semin Pediatr Neurol"},{"issue":"8","key":"6023_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS et al (2021) 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 20(8):653\u2013670. https:\/\/doi.org\/10.1016\/S1474-4422(21)00095-8","journal-title":"Lancet Neurol"},{"issue":"1","key":"6023_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","volume":"77","author":"P Waters","year":"2020","unstructured":"Waters P, Fadda G, Woodhall M et al (2020) Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. JAMA Neurol 77(1):82\u201393. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2940","journal-title":"JAMA Neurol"},{"key":"6023_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejpn.2020.10.006","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Lechner C, Flet-Berliac L et al (2020) E.U. paediatric MOG consortium consensus: part 1 - classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:2\u201313. https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.006","journal-title":"Eur J Paediatr Neurol"},{"key":"6023_CR22","doi-asserted-by":"publisher","unstructured":"Wang XY, Jiang Y, Wu P et al (2024) Less common phenotypes of myelin oligodendrocyte glycoprotein antibody-related diseases in children deserve more attention. Pediatr Res. Published online March 4, 2024. https:\/\/doi.org\/10.1038\/s41390-024-03058-x","DOI":"10.1038\/s41390-024-03058-x"},{"key":"6023_CR23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0000000000004117","volume":"3","author":"Y Hacohen","year":"2017","unstructured":"Hacohen Y, Mankad K, Chong WK et al (2017) Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology 3:269\u2013278. https:\/\/doi.org\/10.1212\/WNL.0000000000004117","journal-title":"Neurology"},{"issue":"14","key":"6023_CR24","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","volume":"26","author":"S Salama","year":"2020","unstructured":"Salama S, Khan M, Shanechi A, Levy M, Izbudak I (2020) MRI differences between MOG antibody disease and AQP4 NMOSD. Mult Scler 26(14):1854\u20131865. https:\/\/doi.org\/10.1177\/1352458519893093","journal-title":"Mult Scler"},{"issue":"10","key":"6023_CR25","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1177\/1352458513484547","volume":"19","author":"LB Krupp","year":"2013","unstructured":"Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19(10):1261\u20131267. https:\/\/doi.org\/10.1177\/1352458513484547","journal-title":"Mult Scler"},{"key":"6023_CR26","doi-asserted-by":"publisher","unstructured":"Armangue T, Oliv\u00e9-Cirera G, Mart\u00ednez-Hernandez E, et al (2020) Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study [published correction appears in Lancet Neurol. 2020 Apr;19(4).  https:\/\/doi.org\/10.1016\/S1474-4422(20)30074-0]. Lancet Neurol 19(3):234\u2013246. https:\/\/doi.org\/10.1016\/S1474-4422(19)30488-0","DOI":"10.1016\/S1474-4422(19)30488-0"},{"key":"6023_CR27","doi-asserted-by":"publisher","unstructured":"Banks SA, Morris PP, Chen JJ, et al (2020) Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. J Neurol Neurosurg Psychiatry. Published online December 28, 2020. https:\/\/doi.org\/10.1136\/jnnp-2020-325121","DOI":"10.1136\/jnnp-2020-325121"},{"key":"6023_CR28","doi-asserted-by":"publisher","unstructured":"Fadda G, Alves CA, O'Mahony J, et al (2021) Comparison of spinal cord magnetic resonance imaging features among children with acquired demyelinating syndromes. JAMA Netw Open 4(10). Published 2021 Oct 1. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28871","DOI":"10.1001\/jamanetworkopen.2021.28871"},{"key":"6023_CR29","doi-asserted-by":"publisher","unstructured":"Rinaldi S, Davies A, Fehmi J et al (2020) Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. Neurol Neuroimmunol Neuroinflamm 8(1). Published 2020 Dec 3. https:\/\/doi.org\/10.1212\/NXI.0000000000000924","DOI":"10.1212\/NXI.0000000000000924"},{"key":"6023_CR30","doi-asserted-by":"publisher","unstructured":"Vazquez Do Campo R, Stephens A, Marin Collazo IV, Rubin DI (2018) MOG antibodies in combined central and peripheral demyelination syndromes. Neurol Neuroimmunol Neuroinflamm 5(6). Published 2018 Sep 11. https:\/\/doi.org\/10.1212\/NXI.0000000000000503","DOI":"10.1212\/NXI.0000000000000503"},{"issue":"4","key":"6023_CR31","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/acn3.52001","volume":"11","author":"P Gupta","year":"2024","unstructured":"Gupta P, Paul P, Redenbaugh V et al (2024) Peripheral nervous system manifestations of MOG antibody associated disease. Ann Clin Transl Neurol 11(4):1046\u20131052. https:\/\/doi.org\/10.1002\/acn3.52001","journal-title":"Ann Clin Transl Neurol"},{"issue":"3","key":"6023_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","volume":"86","author":"M Baumann","year":"2015","unstructured":"Baumann M, Sahin K, Lechner C et al (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 86(3):265\u2013272. https:\/\/doi.org\/10.1136\/jnnp-2014-308346","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"6023_CR33","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1148\/rg.2020200032","volume":"40","author":"A Server Alonso","year":"2020","unstructured":"Server Alonso A, Sakinis T, Pfeiffer HCV, Sandvig I, Barlinn J, Marthinsen PB (2020) Understanding pediatric neuroimmune disorder conflicts: a neuroradiologic approach in the molecular era. Radiographics 40(5):1395\u20131411. https:\/\/doi.org\/10.1148\/rg.2020200032","journal-title":"Radiographics"},{"issue":"1","key":"6023_CR34","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25909","volume":"89","author":"A Cobo-Calvo","year":"2021","unstructured":"Cobo-Calvo A, Ruiz A, Rollot F et al (2021) Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 89(1):30\u201341. https:\/\/doi.org\/10.1002\/ana.25909","journal-title":"Ann Neurol"},{"key":"6023_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00960","volume":"11","author":"E Parrotta","year":"2020","unstructured":"Parrotta E, Kister I (2020) The expanding clinical spectrum of myelin oligodendrocyte glycoprotein (MOG) antibody associated disease in children and adults. Front Neurol 11:960. https:\/\/doi.org\/10.3389\/fneur.2020.00960. (Published 2020 Sep 9)","journal-title":"Front Neurol"},{"issue":"4","key":"6023_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/dmcn.13649","volume":"60","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Rossor T, Mankad K et al (2018) \u2018Leukodystrophy-like\u2019 phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. Dev Med Child Neurol 60(4):417\u2013423. https:\/\/doi.org\/10.1111\/dmcn.13649","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"6023_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/s-0041-1726289","volume":"52","author":"E Yazbeck","year":"2021","unstructured":"Yazbeck E, Maurey H, Leroy C et al (2021) Progressive leukodystrophy-like demyelinating syndromes with MOG-antibodies in children: a rare under-recognized phenotype. Neuropediatrics 52(4):337\u2013340. https:\/\/doi.org\/10.1055\/s-0041-1726289","journal-title":"Neuropediatrics"},{"key":"6023_CR38","doi-asserted-by":"publisher","unstructured":"Wang X, Zhao R, Yang H, Liu C, Zhao Q (2023) Two rare cases of myelin oligodendrocyte glycoprotein antibody-associated disorder in children with leukodystrophy-like imaging findings. BMC Neurol 23(1):247. Published 2023 Jun 27. https:\/\/doi.org\/10.1186\/s12883-023-03294-4","DOI":"10.1186\/s12883-023-03294-4"},{"issue":"1","key":"6023_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00062-020-00929-8","volume":"31","author":"G Barraza","year":"2021","unstructured":"Barraza G, Deiva K, Husson B, Adamsbaum C (2021) Imaging in pediatric multiple sclerosis: an iconographic review. Clin Neuroradiol 31(1):61\u201371. https:\/\/doi.org\/10.1007\/s00062-020-00929-8","journal-title":"Clin Neuroradiol"},{"issue":"3","key":"6023_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S2352-4642(18)30026-9","volume":"2","author":"G Fadda","year":"2018","unstructured":"Fadda G, Brown RA, Longoni G et al (2018) MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health 2(3):191\u2013204. https:\/\/doi.org\/10.1016\/S2352-4642(18)30026-9","journal-title":"Lancet Child Adolesc Health"},{"issue":"11","key":"6023_CR41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","volume":"84","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Paul F, Lana-Peixoto MA et al (2015) MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84(11):1165\u20131173. https:\/\/doi.org\/10.1212\/WNL.0000000000001367","journal-title":"Neurology"},{"key":"6023_CR42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/cen3.12501","volume":"10","author":"Y Miki","year":"2019","unstructured":"Miki Y (2019) Magnetic resonance imaging diagnosis of demyelinating diseases: an update. Clin Exp Neuroimmunol 10:32\u201348. https:\/\/doi.org\/10.1111\/cen3.12501","journal-title":"Clin Exp Neuroimmunol"},{"key":"6023_CR43","doi-asserted-by":"publisher","unstructured":"Tenembaum S, Yeh EA (2021) Guthy-Jackson Foundation International Clinical Consortium (GJCF-ICC) (2020) Pediatric NMOSD: a review and position statement on approach to work-up and diagnosis [published correction appears in Front Pediatr. 8:642203.  https:\/\/doi.org\/10.3389\/fped.2020.642203]. Front Pediatr 8:339. https:\/\/doi.org\/10.3389\/fped.2020.00339","DOI":"10.3389\/fped.2020.642203 10.3389\/fped.2020.00339"},{"key":"6023_CR44","doi-asserted-by":"publisher","unstructured":"Ferilli MAN, Paparella R, Morandini I et al (2021) Pediatric neuromyelitis optica spectrum disorder: case series and literature review. Life (Basel) 12(1):19. Published 2021 Dec 23. https:\/\/doi.org\/10.3390\/life12010019","DOI":"10.3390\/life12010019"},{"issue":"7","key":"6023_CR45","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s10072-023-06686-z","volume":"44","author":"M Salunkhe","year":"2023","unstructured":"Salunkhe M, Gupta P, Singh RK et al (2023) Clinical and radiological spectrum of anti-myelin oligodendrocyte glycoprotein (MOG) antibody encephalitis: single-center observational study. Neurol Sci 44(7):2475\u20132489. https:\/\/doi.org\/10.1007\/s10072-023-06686-z","journal-title":"Neurol Sci"},{"key":"6023_CR46","doi-asserted-by":"publisher","unstructured":"Jurynczyk M, Messina S, Woodhall MR, et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study [published correction appears in brain. 2018 Apr 1;141(4).  https:\/\/doi.org\/10.1093\/brain\/awy014]. Brain 140(12):3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276","DOI":"10.1093\/brain\/awy014 10.1093\/brain\/awx276"},{"key":"6023_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104797","volume":"77","author":"Q Xu","year":"2023","unstructured":"Xu Q, Yang X, Qiu Z et al (2023) Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS. Mult Scler Relat Disord 77:104797. https:\/\/doi.org\/10.1016\/j.msard.2023.104797","journal-title":"Mult Scler Relat Disord"},{"key":"6023_CR48","doi-asserted-by":"publisher","unstructured":"Jarius S, Kleiter I, Ruprecht K, et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation 13(1):281. Published 2016 Nov 1. https:\/\/doi.org\/10.1186\/s12974-016-0719-z","DOI":"10.1186\/s12974-016-0719-z"},{"issue":"7","key":"6023_CR49","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"S Jarius","year":"2023","unstructured":"Jarius S, Aktas O, Ayzenberg I et al (2023) Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol 270(7):3341\u20133368. https:\/\/doi.org\/10.1007\/s00415-023-11634-0","journal-title":"J Neurol"},{"key":"6023_CR50","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejpn.2023.10.005","volume":"47","author":"L Quack","year":"2023","unstructured":"Quack L, Glatter S, Wegener-Panzer A et al (2023) Autoantibody status, neuroradiological and clinical findings in children with acute cerebellitis [published correction appears in Eur J Paediatr Neurol. 2024 Apr 30 (24)00056\u20134. DOI: 10.1016\/j.ejpn.2024.04.010]. Eur J Paediatr Neurol 47:118\u2013130. https:\/\/doi.org\/10.1016\/j.ejpn.2023.10.005","journal-title":"Eur J Paediatr Neurol"},{"key":"6023_CR51","doi-asserted-by":"publisher","unstructured":"Ogawa R, Nakashima I, Takahashi T, et al (2017) MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 4(2). Published 2017 Jan 16. https:\/\/doi.org\/10.1212\/NXI.0000000000000322","DOI":"10.1212\/NXI.0000000000000322"},{"issue":"1","key":"6023_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/ene.13790","volume":"26","author":"L Wang","year":"2019","unstructured":"Wang L, ZhangBao J, Zhou L et al (2019) Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai. China Eur J Neurol 26(1):168\u2013174. https:\/\/doi.org\/10.1111\/ene.13790","journal-title":"China Eur J Neurol"},{"issue":"2","key":"6023_CR53","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ana.26549","volume":"93","author":"C Valencia-Sanchez","year":"2023","unstructured":"Valencia-Sanchez C, Guo Y, Krecke KN et al (2023) Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 93(2):297\u2013302. https:\/\/doi.org\/10.1002\/ana.26549","journal-title":"Ann Neurol"},{"issue":"10","key":"6023_CR54","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s00415-019-09440-8","volume":"266","author":"A Budhram","year":"2019","unstructured":"Budhram A, Mirian A, Le C, Hosseini-Moghaddam SM, Sharma M, Nicolle MW (2019) Unilateral cortical FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome. J Neurol 266(10):2481\u20132487. https:\/\/doi.org\/10.1007\/s00415-019-09440-8","journal-title":"J Neurol"},{"key":"6023_CR55","doi-asserted-by":"publisher","unstructured":"Budhram A, Mirian A, Sharma M (2022) Meningo-cortical manifestations of myelin oligodendrocyte glycoprotein antibody-associated disease: review of a novel clinico-radiographic spectrum. Front Neurol 13:1044642. Published 2022 Oct 20. https:\/\/doi.org\/10.3389\/fneur.2022.1044642","DOI":"10.3389\/fneur.2022.1044642"},{"key":"6023_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2021.782490","volume":"15","author":"H Shu","year":"2022","unstructured":"Shu H, Ding M, Shang P, Song J, Lang Y, Cui L (2022) Myelin oligodendrocyte glycoprotein antibody associated cerebral cortical encephalitis: case reports and review of literature. Front Hum Neurosci 15:782490. https:\/\/doi.org\/10.3389\/fnhum.2021.782490. (Published 2022 Jan 3)","journal-title":"Front Hum Neurosci"},{"key":"6023_CR57","doi-asserted-by":"publisher","unstructured":"Wegener-Panzer A, Cleaveland R, Wendel EM, et al (2020) Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies. Neurol Neuroimmunol Neuroinflamm 7(4). Published 2020 May 1. https:\/\/doi.org\/10.1212\/NXI.0000000000000731","DOI":"10.1212\/NXI.0000000000000731"},{"key":"6023_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00906","volume":"10","author":"J Zhang","year":"2019","unstructured":"Zhang J, Ji T, Chen Q et al (2019) Pediatric autoimmune encephalitis: case series from two Chinese tertiary pediatric neurology centers. Front Neurol 10:906. https:\/\/doi.org\/10.3389\/fneur.2019.00906. (Published 2019 Aug 22)","journal-title":"Front Neurol"},{"issue":"11","key":"6023_CR59","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1177\/08830738211025867","volume":"36","author":"JA Gadde","year":"2021","unstructured":"Gadde JA, Wolf DS, Keller S, Gombolay GY (2021) Rate of leptomeningeal enhancement in pediatric myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. J Child Neurol 36(11):1042\u20131046. https:\/\/doi.org\/10.1177\/08830738211025867","journal-title":"J Child Neurol"},{"issue":"1","key":"6023_CR60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jnnp-2023-331137","volume":"95","author":"P Elsbernd","year":"2023","unstructured":"Elsbernd P, Cacciaguerra L, Krecke KN et al (2023) Cerebral enhancement in MOG antibody-associated disease. J Neurol Neurosurg Psychiatry 95(1):14\u201318. https:\/\/doi.org\/10.1136\/jnnp-2023-331137. (Published 2023 Dec 14)","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6023_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577653","volume":"358","author":"GY Gombolay","year":"2021","unstructured":"Gombolay GY, Gadde JA (2021) Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: a review. J Neuroimmunol 358:577653. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577653","journal-title":"J Neuroimmunol"},{"key":"6023_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104126","volume":"68","author":"S Lin","year":"2022","unstructured":"Lin S, Long W, Wen J, Su Q, Liao J, Hu Z (2022) Myelin oligodendrocyte glycoprotein antibody-associated aseptic meningitis without neurological parenchymal lesions: a novel phenotype. Mult Scler Relat Disord 68:104126. https:\/\/doi.org\/10.1016\/j.msard.2022.104126","journal-title":"Mult Scler Relat Disord"},{"key":"6023_CR63","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pediatrneurol.2024.01.026","volume":"153","author":"A Goldman-Yassen","year":"2024","unstructured":"Goldman-Yassen A, Lee A, Gombolay G (2024) Leptomeningeal enhancement in pediatric anti-myelin oligodendrocyte glycoprotein antibody disease, multiple sclerosis, and neuromyelitis optica spectrum disorder. Pediatr Neurol 153:125\u2013130. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.01.026","journal-title":"Pediatr Neurol"},{"issue":"4","key":"6023_CR64","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3174\/ajnr.A5541","volume":"39","author":"R Zivadinov","year":"2018","unstructured":"Zivadinov R, Ramasamy DP, Hagemeier J et al (2018) Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol 39(4):642\u2013647. https:\/\/doi.org\/10.3174\/ajnr.A5541","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"6023_CR65","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/13524585211034362","volume":"28","author":"D Tzanetakos","year":"2022","unstructured":"Tzanetakos D, Tzartos JS, Vakrakou AG et al (2022) Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: a three-dimensional fluid-attenuated inversion recovery MRI study. Mult Scler 28(5):718\u2013729. https:\/\/doi.org\/10.1177\/13524585211034362","journal-title":"Mult Scler"},{"issue":"4","key":"6023_CR66","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/1352458515593406","volume":"22","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Prelog K, Barnes EH et al (2016) Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 22(4):470\u2013482. https:\/\/doi.org\/10.1177\/1352458515593406","journal-title":"Mult Scler"},{"key":"6023_CR67","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejpn.2020.04.002","volume":"27","author":"EM Wendel","year":"2020","unstructured":"Wendel EM, Baumann M, Barisic N et al (2020) High association of MOG-IgG antibodies in children with bilateral optic neuritis. Eur J Paediatr Neurol 27:86\u201393. https:\/\/doi.org\/10.1016\/j.ejpn.2020.04.002","journal-title":"Eur J Paediatr Neurol"},{"key":"6023_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103709","volume":"60","author":"Y Moon","year":"2022","unstructured":"Moon Y, Lim BC, Chae JH, Jung JH (2022) Clinical characteristics and clinical course of myelin oligodendrocyte glycoprotein antibody-seropositive pediatric optic neuritis. Mult Scler Relat Disord 60:103709. https:\/\/doi.org\/10.1016\/j.msard.2022.103709","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"6023_CR69","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3174\/ajnr.A8089","volume":"45","author":"E George","year":"2024","unstructured":"George E, Russ JB, Validrighi A et al (2024) Clinical and imaging findings in children with myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD): from presentation to relapse. AJNR Am J Neuroradiol 45(2):229\u2013235. https:\/\/doi.org\/10.3174\/ajnr.A8089. (Published 2024 Feb 7)","journal-title":"AJNR Am J Neuroradiol"},{"key":"6023_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.pediatrneurol.2018.03.003","volume":"83","author":"Q Chen","year":"2018","unstructured":"Chen Q, Zhao G, Huang Y et al (2018) Clinical characteristics of pediatric optic neuritis with myelin oligodendrocyte glycoprotein seropositive: a cohort study. Pediatr Neurol 83:42\u201349. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2018.03.003","journal-title":"Pediatr Neurol"},{"issue":"2","key":"6023_CR71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","volume":"89","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Mohammad S, Tantsis E et al (2018) Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 89(2):127\u2013137. https:\/\/doi.org\/10.1136\/jnnp-2017-316880","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6023_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6023_CR73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","volume":"76","author":"D Dubey","year":"2019","unstructured":"Dubey D, Pittock SJ, Krecke KN et al (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA Neurol 76(3):301\u2013309. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4053","journal-title":"JAMA Neurol"},{"key":"6023_CR74","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pediatrneurol.2023.02.019","volume":"143","author":"C Ren","year":"2023","unstructured":"Ren C, Zhang W, Zhou A et al (2023) Clinical and radiologic features among children with myelin oligodendrocyte glycoprotein antibody-associated myelitis. Pediatr Neurol 143:96\u201399. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.02.019","journal-title":"Pediatr Neurol"},{"key":"6023_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1011579","volume":"13","author":"G Fadda","year":"2022","unstructured":"Fadda G, Flanagan EP, Cacciaguerra L et al (2022) Myelitis features and outcomes in CNS demyelinating disorders: comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front Neurol 13:1011579. https:\/\/doi.org\/10.3389\/fneur.2022.1011579. (Published 2022 Nov 7)","journal-title":"Front Neurol"},{"issue":"8","key":"6023_CR76","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp-2015-311743","volume":"87","author":"C Lechner","year":"2016","unstructured":"Lechner C, Baumann M, Hennes EM et al (2016) Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 87(8):897\u2013905. https:\/\/doi.org\/10.1136\/jnnp-2015-311743","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6023_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejpn.2020.10.002","volume":"29","author":"M Baumann","year":"2020","unstructured":"Baumann M, Bartels F, Finke C et al (2020) E.U. paediatric MOG consortium consensus: part 2 - neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:14\u201321. https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.002","journal-title":"Eur J Paediatr Neurol"},{"key":"6023_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejpn.2020.10.005","volume":"29","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wendel EM, Lechner C et al (2020) E.U. paediatric MOG consortium consensus: part 5 - treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. Eur J Paediatr Neurol 29:41\u201353. https:\/\/doi.org\/10.1016\/j.ejpn.2020.10.005","journal-title":"Eur J Paediatr Neurol"},{"issue":"2","key":"6023_CR79","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1352458520907900","volume":"27","author":"E Sechi","year":"2021","unstructured":"Sechi E, Krecke KN, Pittock SJ et al (2021) Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Mult Scler 27(2):303\u2013308. https:\/\/doi.org\/10.1177\/1352458520907900","journal-title":"Mult Scler"},{"issue":"4","key":"6023_CR80","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.neurad.2022.11.003","volume":"50","author":"S Singh","year":"2023","unstructured":"Singh S, Ness J, Marcus L (2023) Myelin oligodendrocyte glycoprotein antibody-associated disease in children: are there MRI predictors of relapse? J Neuroradiol 50(4):382\u2013387. https:\/\/doi.org\/10.1016\/j.neurad.2022.11.003","journal-title":"J Neuroradiol"},{"issue":"5","key":"6023_CR81","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/acn3.51759","volume":"10","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Beukelman T, Hemingway C, Hokkanen SRK, Tennigkeit F, Chitnis T (2023) Attack phenotypes and disease course in pediatric MOGAD. Ann Clin Transl Neurol 10(5):672\u2013685. https:\/\/doi.org\/10.1002\/acn3.51759","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"6023_CR82","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/dmcn.13703","volume":"60","author":"S Duignan","year":"2018","unstructured":"Duignan S, Wright S, Rossor T et al (2018) Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60(9):958\u2013962. https:\/\/doi.org\/10.1111\/dmcn.13703","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"6023_CR83","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75(4):478\u2013487. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4601","journal-title":"JAMA Neurol"},{"key":"6023_CR84","doi-asserted-by":"publisher","unstructured":"Sechi E, Krecke KN, Messina SA, et al (2021) Comparison of MRI lesion evolution in different central nervous system demyelinating disorders. Neurology 97(11). https:\/\/doi.org\/10.1212\/WNL.0000000000012467","DOI":"10.1212\/WNL.0000000000012467"},{"issue":"7","key":"6023_CR85","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/13524585231166834","volume":"29","author":"V Redenbaugh","year":"2023","unstructured":"Redenbaugh V, Chia NH, Cacciaguerra L et al (2023) Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS. Mult Scler 29(7):799\u2013808. https:\/\/doi.org\/10.1177\/13524585231166834","journal-title":"Mult Scler"},{"issue":"2","key":"6023_CR86","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.25957","volume":"89","author":"G Fadda","year":"2021","unstructured":"Fadda G, Banwell B, Waters P et al (2021) Silent new brain MRI lesions in children with MOG-antibody associated disease. Ann Neurol 89(2):408\u2013413. https:\/\/doi.org\/10.1002\/ana.25957","journal-title":"Ann Neurol"},{"key":"6023_CR87","doi-asserted-by":"publisher","unstructured":"Camera V, Holm-Mercer L, Ali AAH, et al (2021) Frequency of new silent MRI lesions in myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder. JAMA Netw Open 4(12). https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.37833","DOI":"10.1001\/jamanetworkopen.2021.37833"},{"issue":"18","key":"6023_CR88","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","volume":"99","author":"SB Syc-Mazurek","year":"2022","unstructured":"Syc-Mazurek SB, Chen JJ, Morris P et al (2022) Frequency of new or enlarging lesions on MRI outside of clinical attacks in patients with MOG-antibody-associated disease. Neurology 99(18):795\u2013799. https:\/\/doi.org\/10.1212\/WNL.0000000000201263. (Published 2022 Oct 31)","journal-title":"Neurology"},{"issue":"4","key":"6023_CR89","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1212\/WNL.0000000000207429","volume":"101","author":"G Fadda","year":"2023","unstructured":"Fadda G, Cardenas de la Parra A, O\u2019Mahony J et al (2023) Deviation from normative whole brain and deep gray matter growth in children with MOGAD, MS, and monophasic seronegative demyelination. Neurology 101(4):e425\u2013e437. https:\/\/doi.org\/10.1212\/WNL.0000000000207429","journal-title":"Neurology"},{"issue":"14","key":"6023_CR90","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1177\/13524585231204414","volume":"29","author":"S Sacco","year":"2023","unstructured":"Sacco S, Virupakshaiah A, Papinutto N et al (2023) Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler 29(14):1736\u20131747. https:\/\/doi.org\/10.1177\/13524585231204414","journal-title":"Mult Scler"},{"key":"6023_CR91","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2023.05.013","volume":"146","author":"KL Harrison","year":"2023","unstructured":"Harrison KL, Gaudioso C, Levasseur VA et al (2023) Central vein sign in pediatric multiple sclerosis and myelin oligodendrocyte glycoprotein antibody-associated disease. Pediatr Neurol 146:21\u201325. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2023.05.013","journal-title":"Pediatr Neurol"},{"issue":"2","key":"6023_CR92","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/13524585211018987","volume":"28","author":"S Messina","year":"2022","unstructured":"Messina S, Mariano R, Roca-Fernandez A et al (2022) Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis. Mult Scler 28(2):217\u2013227. https:\/\/doi.org\/10.1177\/13524585211018987","journal-title":"Mult Scler"},{"issue":"7","key":"6023_CR93","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1136\/jnnp-2020-324826","volume":"92","author":"Y Duan","year":"2021","unstructured":"Duan Y, Zhuo Z, Li H et al (2021) Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. J Neurol Neurosurg Psychiatry 92(7):709\u2013716. https:\/\/doi.org\/10.1136\/jnnp-2020-324826","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"6023_CR94","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","volume":"100","author":"R Cortese","year":"2023","unstructured":"Cortese R, Prados Carrasco F, Tur C et al (2023) Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging. Neurology 100(3):e308\u2013e323. https:\/\/doi.org\/10.1212\/WNL.0000000000201465","journal-title":"Neurology"}],"container-title":["Pediatric Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-024-06023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00247-024-06023-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00247-024-06023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T23:02:57Z","timestamp":1744239777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00247-024-06023-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,7]]},"references-count":94,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["6023"],"URL":"https:\/\/doi.org\/10.1007\/s00247-024-06023-2","relation":{},"ISSN":["1432-1998"],"issn-type":[{"value":"1432-1998","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,7]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}